AR046968A1 - Derivados de amidas sustituidas - Google Patents

Derivados de amidas sustituidas

Info

Publication number
AR046968A1
AR046968A1 ARP040104794A ARP040104794A AR046968A1 AR 046968 A1 AR046968 A1 AR 046968A1 AR P040104794 A ARP040104794 A AR P040104794A AR P040104794 A ARP040104794 A AR P040104794A AR 046968 A1 AR046968 A1 AR 046968A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
alkoxy
alkylamino
hydroxy
Prior art date
Application number
ARP040104794A
Other languages
English (en)
Inventor
Ian Nash
Dearg Brown
John G Cumming
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046968A1 publication Critical patent/AR046968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una sal aceptable para uso farmacéutico del mismo; procesos para su preparacion, composiciones farmacéuticas que los comprenden y su utilizacion en el tratamiento de enfermedades o condiciones médicas aisladas mediadas por citoquinas. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), donde: Qa es fenilo o heteroarilo, y Qa puede llevar opcionalmente 1 o 2 sustituyentes seleccionados entre hidroxi, halogeno, trifluorometilo, ciano, amino, (C1- 6) alquilo, (C2-6) alquenilo, (C2-6) alquinilo, (C1-6) alcoxi, (C1-6) alquilamino, di-[(C1-6)alquil]amino y (C1-6) alcoxicarbonilo; R1 y R2 cada uno se selecciona independientemente entre hidrogeno, (C1-6) alquilo, (C2-6) alquenilo y (C2-6) alquinilo; y Qb es fenilo, heteroarilo o heterociclilo, y Qb puede llevar opcionalmente 1 o 2 sustituyentes seleccionados entre hidroxi, halogeno, (C1-6) alquilo, (C2-6) alquenilo, (C2-6) alquinilo, (C3-6) cicloalquilo, (C3-6)cicloalquil-(C1- 6)alquilo, (C1-6) alcoxi, (C3-6) cicloalcoxi, (C3-6)cicloalquil-(C1-6)alcoxi, carboxi, (C1-6) alcoxicarbonilo, N-(C1-6) alcoxicarbonilo, N,N-di[(C1-6)alquil]carbamoilo, (C2-6) alcanoilo, amino, (C1-6) alquilamino, di-[(C1-6)alquil]amino, halogeno- (C1-6)alquilo, hidroxi-(C1-6)alquilo, (C1-6)alcoxi-(C1-6)alquilo, ciano-(C1-6)alquilo, amino-(C1-6)alquilo, (C1-6)alquilamino-(C1-6)alquilo, di[(C1-6)alquil]amino-(C1-6)alquilo, (C1-6) alquiltio, (C1-6) alquilsulfinilo, (C1-6) alquilsulfonilo, aminosulfonilo, N-(C1-6)alquilsulfamoilo, N,N-di-[(C1-6)alquil]sulfamoilo y (C3-6) cicloalquilsulfonilo; y donde cualquiera de los sustituyentes en Qa o Qb que se definen de aquí en adelante que comprenden un grupo CH2 que se une a 2 átomos de carbono o un grupo CH3 que se une a un átomo de carbono puede llevar opcionalmente en cada dicho grupo CH2 o CH3 uno o más sustituyentes seleccionados entre hidroxi, ciano, amino, (C1-6) alquilo, (C1-6) alcoxi, (C1-6) alquilamino y di-[(C1- 6)alquil]amino; o una sal aceptable para uso farmacéutico del mismo.
ARP040104794A 2003-12-20 2004-12-20 Derivados de amidas sustituidas AR046968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0329572.2A GB0329572D0 (en) 2003-12-20 2003-12-20 Amide derivatives

Publications (1)

Publication Number Publication Date
AR046968A1 true AR046968A1 (es) 2006-01-04

Family

ID=30776197

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104794A AR046968A1 (es) 2003-12-20 2004-12-20 Derivados de amidas sustituidas

Country Status (34)

Country Link
US (3) US7943776B2 (es)
EP (1) EP1699766B1 (es)
JP (1) JP5046650B2 (es)
KR (1) KR101151530B1 (es)
CN (1) CN1918134B (es)
AR (1) AR046968A1 (es)
AT (1) ATE477246T1 (es)
AU (1) AU2004303579B8 (es)
BR (1) BRPI0417844A (es)
CA (1) CA2547617C (es)
CY (1) CY1111980T1 (es)
DE (1) DE602004028656D1 (es)
DK (1) DK1699766T3 (es)
ES (1) ES2350226T3 (es)
GB (1) GB0329572D0 (es)
HK (1) HK1092797A1 (es)
HR (1) HRP20100592T1 (es)
IL (1) IL175998A0 (es)
ME (1) ME01851B (es)
MX (1) MXPA06006660A (es)
MY (1) MY145908A (es)
NO (1) NO337886B1 (es)
NZ (1) NZ547998A (es)
PL (1) PL1699766T3 (es)
PT (1) PT1699766E (es)
RS (1) RS51417B (es)
RU (1) RU2382028C2 (es)
SA (1) SA04250419B1 (es)
SI (1) SI1699766T1 (es)
TW (1) TWI342214B (es)
UA (1) UA88777C2 (es)
UY (1) UY28688A1 (es)
WO (1) WO2005061465A1 (es)
ZA (1) ZA200604973B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ATE482200T1 (de) 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CN101616667A (zh) 2006-10-27 2009-12-30 百时美施贵宝公司 可用作激酶抑制剂的杂环酰胺化合物
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249
WO2009138778A1 (en) * 2008-05-12 2009-11-19 Astrazeneca Ab Cyclopropyl benzamide derivatives as intermediates for cytokine inhibitors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
EP3585768A4 (en) * 2017-02-24 2020-12-23 Taiwanj Pharmaceuticals Co., Ltd. SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE PROPHYLAXIS AND / OR TREATMENT OF AUTOIMMUNE, INFLAMMATORY, OR INFECTIOUS DISEASES
WO2024039864A1 (en) * 2022-08-19 2024-02-22 Purdue Research Foundation Protein:protein interaction inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
EP1062210B1 (en) * 1998-03-09 2005-06-01 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
GB2336362A (en) * 1998-04-17 1999-10-20 Xenova Ltd Cytokine production inhibitors
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
US7263483B2 (en) * 2003-04-28 2007-08-28 Dictaphone Corporation USB dictation device
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
ZA200604973B (en) 2007-05-30
KR101151530B1 (ko) 2012-07-05
US20070135440A1 (en) 2007-06-14
US7943776B2 (en) 2011-05-17
PL1699766T3 (pl) 2011-01-31
BRPI0417844A (pt) 2007-04-17
SI1699766T1 (sl) 2010-12-31
UY28688A1 (es) 2005-07-29
KR20060123352A (ko) 2006-12-01
US20120004243A1 (en) 2012-01-05
ATE477246T1 (de) 2010-08-15
IL175998A0 (en) 2006-10-05
CA2547617A1 (en) 2005-07-07
AU2004303579B8 (en) 2008-05-01
AU2004303579B2 (en) 2008-04-03
CN1918134A (zh) 2007-02-21
CY1111980T1 (el) 2015-11-04
DK1699766T3 (da) 2010-11-01
GB0329572D0 (en) 2004-01-28
HK1092797A1 (en) 2007-02-16
JP2007516979A (ja) 2007-06-28
TWI342214B (en) 2011-05-21
MXPA06006660A (es) 2006-08-11
CN1918134B (zh) 2010-11-10
WO2005061465A1 (en) 2005-07-07
DE602004028656D1 (en) 2010-09-23
JP5046650B2 (ja) 2012-10-10
CA2547617C (en) 2013-02-05
EP1699766A1 (en) 2006-09-13
HRP20100592T1 (hr) 2010-12-31
NO337886B1 (no) 2016-07-04
SA04250419B1 (ar) 2009-01-19
EP1699766B1 (en) 2010-08-11
RU2006125634A (ru) 2008-01-27
AU2004303579A1 (en) 2005-07-07
NO20063330L (no) 2006-09-14
MY145908A (en) 2012-05-15
RU2382028C2 (ru) 2010-02-20
RS51417B (en) 2011-02-28
TW200524620A (en) 2005-08-01
US20130035346A1 (en) 2013-02-07
US8742124B2 (en) 2014-06-03
NZ547998A (en) 2009-03-31
ME01851B (me) 2011-02-28
UA88777C2 (en) 2009-11-25
ES2350226T3 (es) 2011-01-20
PT1699766E (pt) 2010-10-11

Similar Documents

Publication Publication Date Title
AR046968A1 (es) Derivados de amidas sustituidas
AR046308A1 (es) Derivados amida
AR055034A1 (es) DERIVADOS DE 4 OXOQUINAZOLINAS-3-IL-BENZAMIDAS. PROCEDIMIENTOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
AR055017A1 (es) Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
AR035695A1 (es) Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
AR046119A1 (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y / o vegf su preparacion y sus usos como medicamento
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
BR0308146A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AR043449A1 (es) Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
PE20051095A1 (es) DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
PE20070122A1 (es) Proceso para preparar derivados de piperazina azindoloxoacetica sustituida con triazol y nuevas formas de sal producidas de los mismos
JOP20190113A1 (ar) مثبطات بروتون تيروزين كيناز
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
FB Suspension of granting procedure